GRMN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Garmin Ltd (GRMN) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has demonstrated strong financial performance and positive growth trends, the current technical indicators, trading sentiment, and analyst ratings suggest limited upside potential in the short term. Additionally, the absence of strong proprietary trading signals further supports a cautious approach.
The MACD is negatively expanding, RSI is neutral at 44.951, and moving averages are converging, indicating no clear trend. The stock is trading below its pivot level of 237.084, with support at 230.692 and resistance at 243.477. These indicators suggest a bearish to neutral short-term trend.
Strong Q4 2025 financial performance with revenue up 16.59% YoY and net income up 21.33% YoY.
Positive analyst ratings from Tigress Financial and Morgan Stanley, citing growth drivers like AI-enabled services and expanding distribution channels.
Scheduled Q1 2026 earnings report on April 29, 2026, which may provide further clarity on growth prospects.
Hedge funds are selling, with a 1400% increase in selling activity over the last quarter.
BofA maintains an Underperform rating, citing limited upside potential and overvaluation relative to peers.
Recent geopolitical tensions causing GPS disruptions could impact Garmin's satellite navigation business.
In Q4 2025, Garmin reported strong financials with revenue increasing by 16.59% YoY, net income up by 21.33% YoY, and EPS growing by 21.87% YoY. However, gross margin slightly declined by -0.07% YoY to 59.21%. These figures highlight strong growth but also indicate slight margin pressure.
Analyst ratings are mixed. Tigress Financial maintains a Strong Buy with a price target of $320, citing key growth drivers. JPMorgan and Barclays have Neutral and Equal Weight ratings, respectively, with modest price target increases. BofA remains bearish with an Underperform rating and a price target of $220, citing overvaluation concerns.
